With the current cisplatin and carboplatin shortages, for HPV+ H&N patients with indications for concurrent chemoRT, which agent do you recommend next?
What do you primarily use for cisplatin ineligible patients for the concurrent component of chemo-rads for head and neck cancer?
Join Mednetto vote and see how they answered.
The question of 2nd line therapy is difficult due to the dearth of data.
This leaves essentially 3 choices - immunotherapy, cetuximab, or other cytotoxic agents.
Regarding immunotherapy, recent trials for concurrent IO have been mixed, tending to compare IO vs Cetux. The main take-home though, is the...
Join for free or sign in to see the full answer
Altered fractionation, preferably hyper fractionation, and a taxane. If hyper fractionation is not an option, 6-week SIB.
Join for free or sign in to see the full answer
I assume the question is what to use for first line where platinum (cisplatin or carbo/taxol) is indicated for concurrent therapy but unable to access cisplatin or carboplatin due to the national shortage. Unfortunately, this is a real and increasing problem.
If that is the case, I would consider doc...
Join for free or sign in to see the full answer